Scinai Immunotherapeutics Ltd. SCNI

Company Overview

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is an Israel-based biotechnology company focused on the development and commercialization of inflammation and immunology therapeutics, alongside contract development and manufacturing organization (CDMO) services for biologics. The company operates within the biotechnology, immunotherapy, and biopharmaceutical manufacturing industries. Its activities include early-stage therapeutic research, biologics process development, and manufacturing support for biotechnology companies. Scinai’s revenue generation has historically been limited and primarily associated with research collaborations, grants, and CDMO-related activities while it advances proprietary therapeutic assets.

The company traces its origins to BiondVax Pharmaceuticals Ltd., which was founded to develop influenza vaccines using a recombinant protein platform. Following setbacks in late-stage influenza vaccine development, the company restructured and rebranded as Scinai Immunotherapeutics Ltd. in 2023 to emphasize immunology-focused therapeutics and biologics manufacturing services. Scinai’s positioning centers on combining therapeutic development capabilities with biologics manufacturing infrastructure, particularly for early-stage biotech firms seeking development and production support.

Business Operations

Scinai’s operations are organized around two principal activities: proprietary immunotherapeutic development and biologics CDMO services. The company has focused on NanoAb and inflammation-related therapeutic programs through collaborations and platform technologies intended to target immune-mediated diseases. In parallel, its CDMO business provides biologics process development, analytical services, and GMP-oriented manufacturing support for biotechnology customers. The company operates laboratory and manufacturing facilities in Israel designed to support preclinical and early clinical biologics production.

The company’s assets include biologics manufacturing infrastructure, research laboratories, and intellectual property associated with immunotherapy technologies and biologic production processes. Scinai has entered into strategic collaborations with academic institutions and biotechnology partners to advance therapeutic candidates and expand manufacturing utilization. Its operations remain concentrated primarily in Israel, although the company seeks international biotechnology clients and collaboration opportunities through its publicly listed status and industry partnerships.

Strategic Position & Investments

Scinai’s strategic direction has centered on transforming from a single-product vaccine developer into a broader immunotherapy and biologics services platform. Key initiatives have included expanding CDMO capabilities, pursuing licensing opportunities, and investing in therapeutic technologies targeting inflammation and immune-related disorders. Management has emphasized capital-efficient development models and external partnerships as part of the company’s restructuring strategy following the discontinuation of its prior influenza vaccine program.

The company has also explored strategic investments and collaborations involving biologics manufacturing and immunotherapy technologies. Public filings and company disclosures indicate ongoing efforts to leverage its existing infrastructure for service-based revenue generation while selectively advancing proprietary therapeutic assets. Scinai’s emerging focus areas include biologics manufacturing support, immune-modulating therapies, and antibody-related technologies. Available public disclosures indicate that the company remains in an early commercial stage with limited operating revenue relative to established biotechnology peers.

Geographic Footprint

Scinai Immunotherapeutics is headquartered in Jerusalem, Israel, where it maintains its primary research, development, and manufacturing activities. The company’s operational footprint is concentrated mainly within Israel, although its strategic objectives include serving biotechnology customers in North America, Europe, and other international markets through CDMO and collaborative research activities.

As a Nasdaq-listed company, Scinai maintains visibility within international capital markets despite its relatively small operational scale. Its partnerships, investor outreach, and business development initiatives are intended to support broader engagement with global biotechnology and pharmaceutical ecosystems. Publicly available information indicates that most physical operations and personnel remain Israel-based.

Leadership & Governance

Scinai’s leadership team has overseen the company’s transition from influenza vaccine development under the BiondVax name to a diversified immunotherapeutics and biologics services strategy. Governance and strategic direction have emphasized restructuring, operational streamlining, and the pursuit of external collaborations intended to support long-term sustainability and platform expansion.

Key executives and directors have included:

• Amir Reichman – Chief Executive Officer
• Joshua Levine – Chairman of the Board
• Moti Frenkel – Chief Financial Officer
• Ruti Alon – Director
• Yehuda Carmeli – Director

Management communications and public filings indicate a leadership philosophy focused on leveraging existing scientific infrastructure, expanding biologics service capabilities, and pursuing strategic partnerships within immunology and biotechnology markets. Certain executive and board positions have changed periodically as part of the company’s restructuring efforts; publicly available disclosures should be consulted for the most current governance composition.